Mannose binding lectin and prediction of risk for chemotherapy induced febrile neutropenia in patients with a solid tumor

被引：1

作者：

Epskamp, Cynthia ^{[1
]}

Goudzwaard, Jeannette A. ^{[2
]}

Fiets, Edward ^{[3
]}

Zuetenhorst, Johanna M. ^{[1
]}

Polee, Marco B. ^{[3
]}

van de Geijn, Gert-Jan M. ^{[4
]}

van Schaik, Ron H. N. ^{[2
]}

Birnie, Erwin ^{[5
]}

Hamberg, Paul ^{[1
]}

机构：

[1] Franciscus Gasthuis, Dept Internal Med, Postbus 10900, NL-3004 BA Rotterdam, Netherlands

[2] Erasmus MC, Dept Internal Med, Rotterdam, Netherlands

[3] Med Ctr Leeuwarden, Dept Internal Med, Leeuwarden, Netherlands

[4] Franciscus Gasthuis, Dept Clin Chem, Rotterdam, Netherlands

[5] Franciscus Gasthuis, Dept Stat & Educ, Rotterdam, Netherlands

来源：

CANCER INVESTIGATION | 2019年 / 37卷 / 03期

关键词：

Mannose-binding lectin (MBL); Solid tumors; Febrile neutropenia; MBL-; genotype; MBL-deficiency; GENE POLYMORPHISMS; SEVERE INFECTIONS; MBL; ASSOCIATION; DEFICIENCY; FICOLINS;

D O I：

10.1080/07357907.2019.1582660

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Mannose-binding lectin (MBL) - deficient patients who undergo chemotherapy for a solid tumor might have an increased risk developing febrile neutropenia (FN). We investigated in a prospective cohort study relations between MBL-serum levels and polymorphisms in MBL promotor genotypes (-550H/L and -221X/Y) on incidence and severity of FN. Risk of FN was 17.9% in MBL-deficient and 22.5% in MBL-sufficient patients (RR=0.796, p=0.45). Median MBL serum levels at baseline were respectively 1.39 mu g/mL and 1.09 mu g/mL (p=0.92) in patients with and without FN. In conclusion, serum MBL and MBL genotypes (-550H/L and -221X/Y) do not determine the risk for developing FN.

引用

页码：156 / 162

页数：7

共 50 条

[31] Risk of febrile neutropenia among patients receiving CHOP chemotherapy.
Lyman, GH
Dale, DC
Crawford, J
Stolshek, B
Carter, W
Delgado, D
BLOOD, 2001, 98 (11) : 230B - 231B
[32] Self-assessment system of febrile neutropenia (FN) by patients receiving ambulatory chemotherapy for solid tumor.
Kitao, Akihito
Matsumoto, Koji
Tanioka, Maki
Negoro, Shunichi
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[33] FEBRILE NEUTROPENIA INDUCED BY CHEMOTHERAPY OF LUNG CANCER
Sato, M.
Abe, S.
Nakano, H.
Aida, Y.
Nunomiya, K.
Yamauchi, K.
Igarashi, A.
Inoue, S.
Shibata, Y.
Kubota, I.
RESPIROLOGY, 2012, 17 : 114 - 114
[34] Chemotherapy induced febrile neutropenia: management and prevention
Marshall, E.
Innes, H.
CLINICAL MEDICINE, 2008, 8 (04) : 448 - 451
[35] Mannose binding lectin deficiency does not increase usage of antifungals during febrile neutropenia in children - a prospective single institution study
Mudry, P.
Kyr, M. K.
Jarkovsky, J. J.
Sterba, J. S.
Chumchalova, J. Ch.
MYCOSES, 2009, 52 : 87 - 87
[36] Chemotherapy induced neutropenia and febrile neutropenia among breast cancer patients in a tertiary hospital in Nigeria
Salako, Omolola
Okunade, Kehinde Sharafadeen
Adeniji, Adeoluwa Akeem
Fagbenro, Gabriel Timilehin
Afolaranmi, Oluwasegun Joshua
ECANCERMEDICALSCIENCE, 2021, 15
[37] A Risk-Prediction Nomogram for Neutropenia or Febrile Neutropenia after Etoposide-Based Chemotherapy in Cancer Patients: A Retrospective Cohort Study
Zhu, Yu
Guo, Daihong
Kong, Xianghao
Liu, Siyuan
Yu, Chengxuan
PHARMACOLOGY, 2022, 107 (1-2) : 69 - 80
[38] Predicting the risk of severe infection in children with chemotherapy-induced febrile neutropenia
Dubos, Francois
Delebarre, Mathilde
Martinot, Alain
CURRENT OPINION IN HEMATOLOGY, 2012, 19 (01) : 39 - 43
[39] Validation of the FENCE Risk Groups for Prediction of Febrile Neutropenia With First-Cycle Chemotherapy
Zatarah, Razan
Faqeer, Nour
Quraan, Tasnim
Mahmoud, Aseel
Matalka, Lujain
Abu Khadija, Lana
Kamal, Aya
Rimawi, Dalia
JNCI CANCER SPECTRUM, 2022, 6 (03)
[40] Bacteremia in patients with febrile neutropenia following chemotherapy
Vandijck, Dominique M.
Depuydt, Pieter O.
Blot, Stijn I.
Decruyenaere, Johan M.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2008, 12 (04) : 449 - 449

← 1 2 3 4 5 →